Active	Status	Sponsor type	Region	Phase	Filter
9 Active 11 Inactive 20 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Little, Susan
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus	Active, not recruiting	3	719	Japan, US, RoW	Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)	National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies	MPOX	10/24	09/25
NCT05630885: A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV	Completed	2	110	US	CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg	National Institute of Allergy and Infectious Diseases (NIAID), AbbVie	HIV-1-infection	06/24	06/24
NCT04240691: Instacare - Rapid ART Initiation Among Persons With HIV and Out of Care	Completed	N/A	52	US	60-Minutes-For-Health, Time-and-Attention Control Session	University of California, San Diego, Gilead Sciences	Hiv, HIV Infections	09/22	04/24
Cohen, Stuart
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a	Completed	3	407	Europe, Canada, US, RoW	Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir	Eiger BioPharmaceuticals	Hepatitis Delta Virus	10/22	03/23
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus	Active, not recruiting	3	719	Japan, US, RoW	Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)	National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies	MPOX	10/24	09/25
NCT03808922 / 2018-004318-16: Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study	Recruiting	3	274	Europe, US, RoW	DAS181, Placebo, DAS181 COVID-19, DAS181 OL	Ansun Biopharma, Inc.	Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19	08/25	08/25